

EMA/444267/2019

European Medicines Agency decision

P/0280/2019

of 16 August 2019

on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (Taltz), (EMA-001050-PIP02-18-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0280/2019

of 16 August 2019

on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (Taltz), (EMA-001050-PIP02-18-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0352/2018 issued on 20 November 2018,

Having regard to the application submitted by Eli Lilly Nederland B.V. on 25 March 2019 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 June 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the waiver.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for ixekizumab (Taltz), solution for injection, subcutaneous use, including changes to the waiver, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/0090/2012 issued on 29/05/2012, including subsequent modifications thereof.

Article 3

This decision is addressed to Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 - Utrecht, The Netherlands.

EMA/PDCO/224201/2019 **Corr**
Amsterdam, 28 June 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001050-PIP02-18-M01

Active substance(s):

Ixekizumab

Invented name:

Taltz

Condition(s):

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Eli Lilly Nederland B.V.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Eli Lilly Nederland B.V. submitted to the European Medicines Agency on 25 March 2019 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0352/2018 issued on 20 November 2018.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 30 April 2019.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan and to the waiver in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)

2.1.1. Indication(s) targeted by the PIP

Treatment of juvenile idiopathic arthritis (JIA) subsets of Juvenile enthesitis-related arthritis (ERA) including juvenile onset ankylosing spondylitis (JoAS) and juvenile psoriatic arthritis JPsA in paediatric patients from the age of 2 years.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Studies

Area	Number of studies	Description
Quality	1	Study 1 Development of prefilled syringe presentations to accommodate weight strata subcutaneous (SC) dosing in children
Non-clinical	2	Study 2 Repeat-Dose Fertility Study to investigate the potential effects of ixekizumab

		Study 3 PPND Toxicity Study to evaluate development of the F1 offspring, including the immune system, following in utero exposure to ixekizumab
Clinical	1	Study 4 Open label, efficacy, safety, tolerability, pharmacokinetic study of subcutaneous ixekizumab with adalimumab reference arm in children with juvenile idiopathic arthritis subtypes of enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis.
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2023
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of psoriasis

Authorised indication(s):

- Plaque psoriasis

Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

- Psoriatic arthritis

Taltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.

Authorised pharmaceutical form(s):

Solution for injection in pre-filled syringe

Authorised route(s) of administration:

Subcutaneous